Secondary Prevention Bundle for Drug-Related Problems in an Integrated Healthcare Setting: A Pragmatic Observational Implementation-Effectiveness Study.
{"title":"Secondary Prevention Bundle for Drug-Related Problems in an Integrated Healthcare Setting: A Pragmatic Observational Implementation-Effectiveness Study.","authors":"Jordi Fernández-Morató, Jesús Ruiz-Ramos, Mireia Fuster-Barrera, Alícia Antón-López, Eduardo Ortiz-Del Romero, Adrián Plaza-Ruiz, Cristina Roure-I-Nuez","doi":"10.3390/pharmacy14060134","DOIUrl":null,"url":null,"abstract":"<p><p>This study evaluates the implementation and associated 30-day outcomes of the \"Medication Code\" (MC), a secondary prevention bundle for drug-related problems (DRPs), implemented at the Consorci Sanitari de Terrassa (CST), an integrated healthcare organization in Catalonia. The bundle, which combines medication reconciliation, structured medication review, and coordinated communication with primary care, was previously shown to reduce 30-day readmissions in a randomized trial at a large tertiary hospital. Between May 2024 and December 2025, 185 patients attending the emergency department (ED) at CST for a DRP received the secondary prevention intervention bundle. The study assesses the association between implementation of the recommendations and 30-day outcomes, not the effect of the MC bundle itself. Treatment optimization proposals were implemented in 72.4% of patients, either at discharge or during primary care follow-up, supported by a multiprofessional integrated team of pharmacists and primary care practitioners. Implementation of the pharmacotherapeutic proposals was associated with an absolut risk reduction of 30-day ED revisits and DRP-related readmissions. These findings are consistent with previous observations from the original MC program. However, because all included patients received the intervention bundle and outcomes were compared according to implementation status, the study cannot estimate the effectiveness of the MC bundle itself.</p>","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"14 6","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13610349/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/pharmacy14060134","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
This study evaluates the implementation and associated 30-day outcomes of the "Medication Code" (MC), a secondary prevention bundle for drug-related problems (DRPs), implemented at the Consorci Sanitari de Terrassa (CST), an integrated healthcare organization in Catalonia. The bundle, which combines medication reconciliation, structured medication review, and coordinated communication with primary care, was previously shown to reduce 30-day readmissions in a randomized trial at a large tertiary hospital. Between May 2024 and December 2025, 185 patients attending the emergency department (ED) at CST for a DRP received the secondary prevention intervention bundle. The study assesses the association between implementation of the recommendations and 30-day outcomes, not the effect of the MC bundle itself. Treatment optimization proposals were implemented in 72.4% of patients, either at discharge or during primary care follow-up, supported by a multiprofessional integrated team of pharmacists and primary care practitioners. Implementation of the pharmacotherapeutic proposals was associated with an absolut risk reduction of 30-day ED revisits and DRP-related readmissions. These findings are consistent with previous observations from the original MC program. However, because all included patients received the intervention bundle and outcomes were compared according to implementation status, the study cannot estimate the effectiveness of the MC bundle itself.
本研究评估了“药物代码”(MC)的实施和相关的30天结果,MC是药物相关问题(DRPs)的二级预防捆绑包,在加泰罗尼亚的综合医疗保健组织Consorci Sanitari de Terrassa (CST)实施。该方案结合了药物调节、结构化药物审查和与初级保健的协调沟通,先前在一家大型三级医院的随机试验中显示可以减少30天的再入院率。在2024年5月至2025年12月期间,185名在CST急诊科(ED)接受DRP的患者接受了二级预防干预。该研究评估了建议的实施与30天结果之间的关系,而不是MC包本身的效果。72.4%的患者在出院时或初级保健随访期间实施了治疗优化建议,并得到了由药剂师和初级保健医生组成的多专业综合团队的支持。药物治疗建议的实施与30天ED复诊和drp相关再入院的绝对风险降低有关。这些发现与先前原始MC计划的观察结果一致。然而,由于所有纳入的患者都接受了干预包,并且根据实施情况对结果进行了比较,因此本研究无法估计MC包本身的有效性。